Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ANIK
#3330
Anika Therapeutics Inc. - Common Stock
20.5
6
USD
0.00%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.44%
Monthly Change
-1.44%
6 month change
+38.08%
Year Change
+102.76%
Previous Close
20.4
7
Open
20.4
7
Low
20.0
0
High
20.7
7
Markets
US Stock Market
Healthcare
Drug Manufacturers—Specialty & Generic
ANIK
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
14.33 M
14.47 M
14.63 M
14.85 M
14.18 M
13.4 M
13.38 M
Valuation ratios
Enterprise value
552.74 M
423.97 M
345.05 M
263.63 M
177.71 M
71.3 M
228.85 M
Price to earnings ratio
-26.78
127.96
-28.9
-4.02
-4.3
-12.64
-73.96
Price to sales ratio
4.93
3.55
2.75
1.99
2.02
1.22
—
Price to cash flow ratio
49.27
62.44
97.36
-185.74
44.85
12.32
50.97
Price to book ratio
2.36
1.83
1.5
1.56
1.57
0.96
0.5
Enterprise value to EBITDA ratio
11.81
5.18
5.96
-26.72
3.99
1.63
—
Profitability ratios
Return on assets %
-0.07
0.01
-0.04
-0.31
-0.28
-0.06
0.02
Return on equity %
-0.09
0.01
-0.05
-0.39
-0.37
-0.08
0.02
Return on invested capital %
-50.18
1.3
-28.3
-200.62
20.05
-51.44
8.94
Gross margin %
52.91
56.12
59.89
61.85
63.38
56.56
65.15
Operating margin %
-21.71
1.77
-12.42
-52.58
-4.25
-9.8
9.06
EBITDA margin %
35.89
55.42
37.05
-5.92
37.12
38.79
48.51
Net margin %
-18.38
2.8
-9.51
-49.6
-47.02
-9.64
10.15
Liquidity ratios
Quick ratio
3.56
4.45
4.65
3.76
3.85
3.86
3.19
Current ratio
4.81
5.66
6.07
5.26
4.88
4.72
4.48
Inventory turnover
1.8
1.58
1.65
1.48
1.25
2.61
0.4
Asset turnover
0.37
0.41
0.45
0.54
0.51
0.59
0.18
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.92
0.57
0.3
-0.12
0.37
0.78
0.39
EBIT per share
2.33
4.61
2.97
-1.64
2.64
2.65
2.89
EBITDA per share
3.29
5.6
3.98
-0.67
3.02
3.05
3.33
Total debt per share
—
—
—
—
—
—
—
Cash per share
6.91
6.45
8.31
7.43
5.38
5.66
2.8
Net current asset value per share
12.47
11.52
11.64
11.14
7.72
7.21
7.23
Tangible book value per share
19.15
19.62
19.61
14.48
10.46
10.01
10.01
Working capital per share
9.88
9.48
9.73
9.02
6.14
5.68
5.62
Book value per share
19.15
19.62
19.61
14.48
10.46
10.01
10.01
News
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study